89 related articles for article (PubMed ID: 8615134)
1. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
[No Abstract] [Full Text] [Related]
2. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
3. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
[TBL] [Abstract][Full Text] [Related]
4. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
6. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
7. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Nomoto M; Fukuda T
Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
[No Abstract] [Full Text] [Related]
8. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Gomez-Mancilla B; Bédard PJ
Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
[TBL] [Abstract][Full Text] [Related]
9. D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates.
Meschler JP; Clarkson FA; Mathews PJ; Howlett AC; Madras BK
J Pharmacol Exp Ther; 2000 Mar; 292(3):952-9. PubMed ID: 10688609
[TBL] [Abstract][Full Text] [Related]
10. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
Rowlett JK; Platt DM; Yao WD; Spealman RD
J Pharmacol Exp Ther; 2007 Jun; 321(3):1135-43. PubMed ID: 17351103
[TBL] [Abstract][Full Text] [Related]
11. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists.
Khroyan TV; Barrett-Larimore RL; Rowlett JK; Spealman RD
J Pharmacol Exp Ther; 2000 Aug; 294(2):680-7. PubMed ID: 10900248
[TBL] [Abstract][Full Text] [Related]
13. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
14. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
[No Abstract] [Full Text] [Related]
15. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
[TBL] [Abstract][Full Text] [Related]
16. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
17. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
18. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
